J&J Wins Risperdal Verdict Cut, Must Pay State $136 Million
This article is for subscribers only.
South Carolina’s highest court cut a $327 million verdict against Johnson & Johnson by more than half while refusing to throw out a jury’s finding the company deceptively marketed the antipsychotic drug Risperdal in the first state case over the medicine to survive an appeal.
The ruling conflicts with decisions by two other state’s high courts. Last year, J&J persuaded supreme courts in Arkansas and Louisiana to throw out awards totaling $1.5 billion over deceptive-marketing claims tied to Risperdal.